Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: J Womens Health (Larchmt). 2018 Aug 10;27(11):1335–1341. doi: 10.1089/jwh.2018.6947

Table 3.

Unadjusted Rate of Physician-Reported Adherence to Recommendations Against Ovarian Cancer Screening by Patient, Physician, and Practice Characteristics

All physicians (n = 497)
Total 71.8
Patient characteristics
 Age (years)
  35 72.4
  51 71.3
 Race
  African American 72.6
  Caucasian 70.1
 Insurance typea
  Private 67.8
  Medicaid 76.5
 Requested ovarian cancer screeningb
  Yes 63.9
  No 79.7
Physician and practice characteristics
 Age (years)
  30–39 78.7
  40–49 73.4
  50–64 66.7
 Sex
  Female 73.8
  Male 70.4
 Specialtyc
  Family medicine 72.8
  Obstetrics-gynecology 60.5
  General internal medicine 76.0
 Board certification
  Yes 73.1
  No 58.3
 Years in practice
  0–10 75.2
  11–20 72.7
  21+ 69.6
 Practice typeb
  Solo practice 57.4
  Group practice or other practice type 76.3
 Weekly average number of patients
  1–60 76.9
  61–90 75.6
  91+ 65.5
 Involved in clinical teaching
  Yes 72.9
  No 70.8
 Geographic location
  Small rural/remote rural 66.8
  Large rural 69.0
  Urban 72.6
 Census division
  New England 59.5
  Middle Atlantic 65.5
  East North Central 80.8
  West North Central 67.8
  South Atlantic 76.2
  East South Central 68.0
  West South Central 63.4
  Mountain 64.2
  Pacific 77.0
 Level of risk taking
  Low (6–17) 71.8
  Medium (18–24) 71.7
  High (25+) 71.8
 Fear of malpractice
  Low (2–4) 73.5
  Medium (5–7) 77.2
  High (8+) 68.8
 USPSTF among top three sources of cancer screening informationb
  Yes 79.6
  No 623
 NIH/NCI among top three sources of cancer screening informationa
  Yes 65.9
  No 75.0
 ACOG among top three sources of cancer screening information
  Yes 67.4
  No 73.9
 ACS among top three sources of cancer screening information
  Yes 70.6
  No 74.0
 TVU is clinically effective in screening for ovarian cancerb
  Agree 48.1
  Disagree 81.0
 CA125 is clinically effective in screening for ovarian cancerb
  Agree 40.2
  Disagree 79.3
 Either TVU or CA125 is clinically effective in screening for ovarian cancerb
  Agree 47.7
  Disagree 82.9
a

p ≤ 0.05

b

p ≤ 0.001

c

p ≤ 0.01.

Results were adjusted using weights to represent the specialty distribution of the practicing U.S. physician population of family physicians, general internists, and obstetrician-gynecologists.